|
Dialysis patient robbed after arriving home from treatment - Fox 59 |
 |
 |
|
INDIANAPOLIS (Aug. 4, 2015) – Indianapolis Metropolitan Police are looking for two suspects who broke into a west side home, then robbed a man who had just finished dialysis treatment.
Jaime Lopez, 52, told police he had spent the early part of Monday receiving dialysis treatment at a local hospital. He was still feeling weakened from the treatment as he walked up toward the steps of his back door in the 2400 block of Goodlet Avenue. Suddenly, he was approached by a masked man running out his door.
“I guess they heard his footsteps,” said Lopez’s nephew, Uribe Lopez. “And that’s when one of them came out running with a gun.”
“No one expects to come home in broad daylight and be confronted with two armed individuals with masks and gloves on,” said IMPD Lt. Richard Riddle.
Lopez says the suspect held him at gunpoint and forced him to sit on a bench and stare at the wall of the house, while the second suspect continued ransacking the house inside.
“To me, it would have made me feel like my life was over,” Uribe Lopez said.
After several minutes, the two suspects ran off carrying cash, electronics and about $10,000 worth of gold jewelry. Every room in the house had been rifled through, with beds overturned and clothing and other items tossed about. Jaime Lopez, who only speaks Spanish, then called his nephew about the incident.
“They were smart,” Uribe Lopez said. “They took all the gold and left the things that wasn’t gold.”
Members of the Lopez family don’t know if the suspects knew the house would be empty when they broke in. It’s possible that they saw Jaime leave for the hospital around 6 a.m. Family members are thankful the break-in happened while Jaime was away.
“If he would have been here they might have hurt him,” Uribe Lopez said.
The family also says a storage facility next door to the house was broken into last week. They suspect the same people may have been involved in both incidents.
“We don’t want individuals thinking they can prey on anybody in the neighborhoods,” Riddle said. “Especially people who may not speak English and be able to properly alert authorities. That’s a concern of ours.”
|
|
Dr Subal Pradhan brings pediatric nephrology to Sishu Bhawan - Odisha Sun Times |
|
|
|
Odisha Sun Times Bureau
Cuttack, Aug 5:
Sardar Vallav Bhai Patel Post Graduate Institute of Pediatrics (Sishu Bhawan), the largest referral Government teaching hospital of Odisha, received a shot in the arm recently with Dr Subal Pradhan, the first Indian to receive advanced training at the pediatric nephrology association (IPNA) in McGill Health University, Canada, returning to the institution after his training.
Dr Pradhan, who received his basic training in pediatrics Nephrology from St. John, Bangalore is working as an Assistant Professor at Sishu Bhawan..
Pediatric Nephrology is a relatively less recognized specialty compared to adult nephrology service in India. Renal diseases in children are different from those in adults and so are its diagnosis and management. In adults, the common causes of renal problems are diabetes, hypertension and immunological diseases whereas in children the are due to infection, congenital birth defects and familial renal disease.
Many kidney diseases start in early childhood. If not treated appropriately, they can lead to permanent kidney failure in late childhood or adult life. Besides malaria, dengue and snake bite are important causes of acute kidney failure (ARF),increasing the renal disease burden in Odisha.
So far there is no established pediatrics nephrology service in Odisha. Provision of pediatric nephrology care at Sishu Bhawan will be great benefit to the children with renal problems in Odisha.
|
|
|
Kidney Dialysis Equipment Market – Global Industry Size, Trends, Share ... - Medgadget.com (blog) |
|
|
The dialysis industry is growing at a significant rate due to increase in the prevalence of organ failure, growing awareness in the field, and rise in adoption rate of dialysis. The dialysis industry encompasses various other industries, including medical devices and health care services. Medical devices include dialysis products and supplies, whereas health care services include dialysis services, which require skilled professionals to execute the process successfully. Kidney dialysis equipment refers to the medical devices that are used for eliminating wastes and unwanted water from the blood. They are used in case of patients with failed or damaged kidney. Various causes of kidney failure include diabetes, hypertension, malaria, glomerulonephritis, polycystic kidney disease, long-term exposure to lead, solvents and fuels, jaundice, over consumption of some medications, yellow fever, and others. On the basis of types, kidney dialysis equipment may be classified into hemodialysis and peritoneal dialysis. Two main principles of peritoneal dialysis are Continuous Ambulatory Peritoneal Dialysis (CAPD) and Continuous Cyclic Peritoneal Dialysis (CCPD). Kidney dialysis equipment may be used in dialysis centers, hospitals, or home care settings.
Buy Full Kidney Dialysis Equipment Market Report: http://www.persistencemarketresearch.com/market-research/kidney-dialysis-equipment-market.asp
North America, followed by Europe, dominates the global market for kidney dialysis equipment due to the presence of a large aging population and availability of better health care facilities in the region. In addition, there is a high prevalence of kidney diseases in the region. According to The Centers for Disease Control and Prevention (CDC), a public health institute in the U.S., in 2014, more than 20 million people suffered from chronic kidney diseases. Asia is expected to grow at a high rate in the next few years in the global kidney dialysis equipment market. China and India are expected to be the fastest growing markets for kidney dialysis equipment in Asia. Some of the key driving forces for the kidney dialysis equipment market in emerging countries are increasing R&D investment, presence of a large pool of patients, rising government funding, and growing level of awareness among people.
Diseases such as obesity accelerate the incidences of kidney failure. In addition, habits such as smoking lead to an increase in incidences of kidney failure. Increasing patient pool, rising awareness about treatment of kidney malfunction, and improved government funding are some of the key factors driving the global kidney dialysis equipment market. In addition, introduction of safer procedures for renal dialysis is driving the market. However, factors such as the high costs involved and lack of skilled professionals to carry out the process successfully, are restraining the growth of the kidney dialysis equipment market.
Growing demographics and economies in developing countries, such as India and China, are expected to create good opportunities for the global kidney dialysis equipment market. The introduction of some new products with better efficiency is also expected to offer good opportunities for the global kidney dialysis equipment market. Rising number of mergers and acquisitions, new product launches, and increasing number of collaborations and partnerships are some of the latest trends that have been observed in the global kidney dialysis equipment market. Complications associated with kidney dialysis are a challenge for the market. Some of the key companies operating in the kidney dialysis equipment market are Baxter International, Inc., B. Braun Melsungen AG, Sorin Group, and Teleflex Medical. Other companies which have a significant presence in the kidney dialysis equipment market include DaVita, Inc., Nikkiso Co., Ltd., Rockwell Medical Technologies, Inc., Gambro AB, Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Kuraray Medical Co., Ltd, NxStage Medical, Inc., Aksys Ltd., and Diaverum.
Request Full TOC: http://www.persistencemarketresearch.com/toc/4487
Key Points Covered in the Report
- Market segmentation on the basis of type, application, product, and technology (as applicable)
- Geographic segmentation
- Market size and forecast for the various segments and geographies for the period from 2010 to 2020
- Company profiles of the leading companies operating in the market
- Porter’s Five Forces Analysis of the market
Visit PMR Blog: http://pmrblog.com/
About Us:
Persistence Market Research (PMR) is a U.S.-based full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs.
PMR stands committed to bringing more accuracy and speed to clients’ business decisions. From ready-to-purchase market research reports to customized research solutions, PMR’s engagement models are highly flexible without compromising on its deep-seated research values.
Contact:
Addie Thomes
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Web: http://www.persistencemarketresearch.com
|
|
Rockwell Medical Reports Second Quarter 2015 Results - CNNMoney |
|
|
|
WIXOM, Mich., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, reported results for the second quarter of 2015.
Q2 2015 Financial Highlights
- Sales were $13.0 million, in line with Q2 2014.
- Gross profit was $2.1 million, a 2.3% increase over Q2 2014.
- Gross profit margins increased to 15.9% compared to 15.5% in Q2 2014.
- R&D expense was $0.9 million compared to $0.8 million in Q1 2015.
- Net loss was ($2.5) million or ($0.05) per share, compared to a net loss of ($3.2) million or ($0.08) per share in Q2 2014, a $.03 per share improvement.
- Cash and investments were $77.3 million as of June 30, 2015.
YTD 2015 Financial Highlights
- Sales in the first six months of 2015 were $26.8 million compared to $26.0 million in the first six months of 2014.
- Gross profit was $4.4 million, an 18.4% increase over the first six months of 2014.
- Gross profit margins increased to 16.3% compared to 14.2% in the first six months of 2014.
- R&D expense was $1.7 million compared to $4.8 million in the first six months of 2014.
- Net loss was ($6.2) million or ($0.12) per share, compared to a net loss of ($11.0) million or ($0.28) per share in the first six months of 2014, a $0.16 per share improvement.
2015 YTD Corporate Highlights
- Obtained U.S. FDA drug approval to market Triferic™ (ferric pyrophosphate citrate) for iron replacement and hemoglobin maintenance in hemodialysis patients.
- Received U.S. CMS Q-Code assignment for reimbursement of Triferic; effective July 1, 2015.
- Increased manufacturing and product inventory ahead of commercial drug launches.
- Increased marketing and advertising in preparation for commercial drug launches.
- PRIME ESA Sparing Study published in Kidney International.
- CRUISE 1-2 Phase 3 Studies published in Nephrology Dialysis Transplantation.
- Triferic clinical data presented at the National Kidney Foundation Spring Meeting and Annual Dialysis Conference both in the U.S., and ERA-EDTA Congress in Europe.
"As expected, we had another solid quarter," stated Robert L. Chioini, Chairman and CEO of Rockwell. "Our focus and effort the last five months has been on performing the necessary work to launch Triferic commercially, as well as Calcitriol. Since our FDA approval of Triferic, interest from the clinical community in gaining access to the drug has been strong across large and small dialysis organizations. Short-term pilot evaluations are being coordinated among some of the larger groups to establish internal protocol, prior to clinic-wide use. We anticipate these pilot studies will begin in the next few weeks. Once internal protocols are established and working satisfactorily, we expect to see broad-based clinical adoption of Triferic.
Conference Call Information
Rockwell Medical will be hosting a conference call to review its second quarter 2015 results on Tuesday, August 4, 2015 at 4:30 pm ET. Investors are encouraged to call a few minutes in advance at (877) 383-7438, or for international callers (678) 894-3975, passcode # 82154892 or to listen to the call via webcast at the Rockwell Medical IR web page: http://ir.rockwellmed.com/
About Triferic
Triferic is a unique iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron loss that occurs during their dialysis treatment. Triferic is introduced into bicarbonate concentrate, on-site at the dialysis clinic, and subsequently mixed into dialysate. Once in dialysate, Triferic crosses the dialyzer membrane and enters the blood where it immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. In completed clinical trials, Triferic has demonstrated that it can effectively deliver sufficient iron to the bone marrow and maintain hemoglobin, without increasing iron stores (ferritin). Please visit www.triferic.com for more information.
About Rockwell Medical
Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.
Rockwell's recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. In completed clinical trials, Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market.
Rockwell's FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.
Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell's products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell has three manufacturing/distribution facilities located in the U.S.
Rockwell's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell's intention to launch Calcitriol and Triferic following FDA approval. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan", "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical's SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.
Triferic™ is a trademark of Rockwell Medical, Inc.
CONTACT: Michael Rice, Investor Relations; 646-597-6979
 
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
